ETAHX Fees and Costs — Eventide Healthcare & Life Sciences Fund, Class A
Data updated: 2026-09-11
The net expense ratio is 1.56%: a 1.10% management fee, a 0.25% 12b-1 fee plus 0.21% other expenses. This share class carries a maximum front-end sales load of 5.75% and a deferred sales charge of up to 1.00%. In fiscal 2026 the fund paid $2.5M in broker commissions, 0.1631% of average net assets, and portfolio turnover was 41%.
ETAHX Fees and Expenses
Annual operating expenses and sales charges of ETAHX. Prospectus, as of November 4, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 1.10% |
| 12b-1 fee | 0.25% |
| Other expenses | 0.21% |
| Gross expense ratio | 1.56% |
| Fee waiver | — |
| Net expense ratio | 1.56% |
| Sales charges | |
|---|---|
| Max front load | 5.75% |
| Max deferred load | 1.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | Yes |
ETAHX Costs Over Time
On $10,000 invested in ETAHX, assuming 5% a year before costs, total costs come to $1,735 over 5 years, cutting the return by 3.02% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $672 | $575 | $575 |
| Fund expenses (net expense ratio 1.56%) | $154 | $478 | $823 |
| Trading costs (broker commissions) | $16 | $50 | $86 |
| Lost growth on money paid in costs | $29 | $117 | $251 |
| Total costs | $872 | $1,220 | $1,735 |
| Value after costs | $9,628 | $10,356 | $11,028 |
| Impact on return, per year | 8.72% | 3.83% | 3.02% |
ETAHX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending June 30, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.1631%
- Total broker commissions: $2.5M
- Bought from dealers (principal trades, not a cost): $222.6M
- Portfolio turnover (prospectus): 41%
- Securities lending: none during the year
ETAHX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES GROUP | $404K | 23.67% |
| VIRTU FINANCIAL | $358K | 20.99% |
| LEERINK SWANN & CO | $200K | 11.69% |
| COWEN GROUP | $143K | 8.40% |
| GOLDMAN SACHS | $134K | 7.87% |
| PIPER SANDLER & CO. | $128K | 7.52% |
| JPMORGAN CHASE | $108K | 6.35% |
| CANTOR FITZGERALD | $83K | 4.85% |
| ADVISORS ASSET MGMT | $75K | 4.42% |
| MORGAN STANLEY SMITH BARNEY | $73K | 4.25% |
ETAHX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| MORGAN STANLEY SMITH BARNEY | $68.2M | 30.65% |
| JPMORGAN CHASE | $44.0M | 19.75% |
| JEFFERIES GROUP | $42.8M | 19.21% |
| COWEN GROUP | $23.7M | 10.67% |
| BANK OF AMERICA MERRILL LYNCH | $22.7M | 10.21% |
| PIPER SANDLER & CO. | $11.2M | 5.03% |
| CANTOR FITZGERALD | $5.0M | 2.25% |
| LEERINK SWANN & CO | $5.0M | 2.25% |
Eventide Healthcare & Life Sciences Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| ETIHX | Class I | 1.31% | none |
| ETNHX | Class N | 1.51% | none |
| ETAHX | Class A | 1.56% | 5.75% |
| ETCHX | Class C | 2.31% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.